NCT02393950View on ClinicalTrials.gov

Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

March 31, 2016

Conditions
Healthy Volunteer Study
Interventions
DRUG

ODM-106

Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

DRUG

Placebo

Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

Trial Locations (1)

Unknown

Parexel International GmbH, Berlin

All Listed Sponsors
lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT02393950 - Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers | Biotech Hunter | Biotech Hunter